Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IM Cannabis Corp ( (IMCC) ) has issued an announcement.
On September 15, 2025, IM Cannabis Corp. announced significant changes to its Board of Directors, with the resignation of Shmulik Arbel and Brian Schinderle, and the appointment of Asaf Yitzhaik and Eli Zamir as their replacements. The company also appointed Oz Adler as the new Chairman of the Board. These changes are part of a strategic review aimed at exploring additional business opportunities to enhance long-term growth and shareholder value.
The most recent analyst rating on (IMCC) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on IM Cannabis Corp stock, see the IMCC Stock Forecast page.
Spark’s Take on IMCC Stock
According to Spark, TipRanks’ AI Analyst, IMCC is a Underperform.
IM Cannabis Corp’s overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and negative cash flows. The technical analysis also indicates a bearish trend, further contributing to the low score. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on IMCC stock, click here.
More about IM Cannabis Corp
IM Cannabis Corp. is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company focuses on sustainable and profitable growth in these high-value markets through a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain.
Average Trading Volume: 89,355
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.13M
For an in-depth examination of IMCC stock, go to TipRanks’ Overview page.